From 86535306d6dd1614f61316cd43b719dc21de15bc Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Thu, 30 Apr 2026 22:33:53 +0000 Subject: [PATCH] vida: extract claims from 2026-04-28-noom-glp1-companion-biomarker-integration-2025 - Source: inbox/queue/2026-04-28-noom-glp1-companion-biomarker-integration-2025.md - Domain: health - Claims: 0, Entities: 0 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida --- ...20-percentage-points-through-coaching-and-monitoring.md | 7 +++++++ ...es-profitable-and-behavioral-only-companies-bankrupt.md | 7 +++++++ ...04-28-noom-glp1-companion-biomarker-integration-2025.md | 5 ++++- 3 files changed, 18 insertions(+), 1 deletion(-) rename inbox/{queue => archive/health}/2026-04-28-noom-glp1-companion-biomarker-integration-2025.md (98%) diff --git a/domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md b/domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md index 545e5e217..ee243a7da 100644 --- a/domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md +++ b/domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md @@ -46,3 +46,10 @@ Omada's Enhanced GLP-1 Care Track achieved 67% persistence at 12 months versus 4 **Source:** PHTI December 2025 employer report 34% of employers now mandate behavioral support as a coverage condition (up from 10%), and three major payers (Evernorth, Optum Rx, UHC) have operationalized behavioral support as prerequisite infrastructure. This represents market-wide validation that behavioral support improves persistence enough to justify mandatory implementation at the payer level. + + +## Supporting Evidence + +**Source:** Noom 2025 performance data, Pharmaceutical Commerce + +Noom's microdose GLP-1Rx users showed 77.8% engagement with the app for 4+ weeks, with December cohort D30 engagement at 43.6% (10x+ higher than average health/medical/fitness app retention of 4.3%). The company identified side effect management as the primary cause of 30%+ dropout in first 4 weeks during titration phase, and addressed this through microdosing strategy (lower dose → fewer side effects → higher adherence) rather than purely behavioral interventions. diff --git a/domains/health/glp1-behavioral-support-market-stratifies-by-physical-integration-with-atoms-to-bits-companies-profitable-and-behavioral-only-companies-bankrupt.md b/domains/health/glp1-behavioral-support-market-stratifies-by-physical-integration-with-atoms-to-bits-companies-profitable-and-behavioral-only-companies-bankrupt.md index ae683300e..c228bc7a2 100644 --- a/domains/health/glp1-behavioral-support-market-stratifies-by-physical-integration-with-atoms-to-bits-companies-profitable-and-behavioral-only-companies-bankrupt.md +++ b/domains/health/glp1-behavioral-support-market-stratifies-by-physical-integration-with-atoms-to-bits-companies-profitable-and-behavioral-only-companies-bankrupt.md @@ -45,3 +45,10 @@ WeightWatchers post-bankruptcy strategy (July 2025) explicitly avoids CGM integr **Source:** WW International post-bankruptcy clinical strategy, December 2025 WeightWatchers' post-bankruptcy (May 2025) strategy shows selective CGM deployment: Abbott FreeStyle Libre integration for WW Diabetes Program (6-month RCT showing 0.9 HbA1c reduction, 33.8% depression symptom reduction, 62% physical function increase), but NO CGM integration for general GLP-1/obesity Med+ program. The Med+ program uses only AI body scanner and photo-based food tracking—no physical data generation. This selective deployment suggests WW recognizes the atoms-to-bits moat but constrains it to diabetes where CGM reimbursement is established, not extending to the obesity market where Omada (CGM + behavioral + prescribing, profitable, $260M revenue, IPO June 2025) is winning. + + +## Extending Evidence + +**Source:** Noom press releases + Pharmaceutical Commerce, December 2025 + +Noom's December 2025 'Proactive Health Microdose GLP-1Rx' program ($149/month) combines microdosed GLP-1 with at-home biomarker testing every four months, representing a distinct atoms-to-bits integration strategy from Omada's continuous CGM monitoring. This periodic biomarker testing approach (quarterly) vs. continuous monitoring (daily) represents two different physical-to-digital integration strategies with different cost/adherence tradeoffs. Noom achieved $100M revenue run-rate within four months of launching GLP-1 programs in September 2024, demonstrating that periodic biomarker testing can be commercially viable as a physical integration layer. diff --git a/inbox/queue/2026-04-28-noom-glp1-companion-biomarker-integration-2025.md b/inbox/archive/health/2026-04-28-noom-glp1-companion-biomarker-integration-2025.md similarity index 98% rename from inbox/queue/2026-04-28-noom-glp1-companion-biomarker-integration-2025.md rename to inbox/archive/health/2026-04-28-noom-glp1-companion-biomarker-integration-2025.md index f26ad53dc..f0a4a5a65 100644 --- a/inbox/queue/2026-04-28-noom-glp1-companion-biomarker-integration-2025.md +++ b/inbox/archive/health/2026-04-28-noom-glp1-companion-biomarker-integration-2025.md @@ -7,10 +7,13 @@ date: 2025-12-01 domain: health secondary_domains: [] format: news -status: unprocessed +status: processed +processed_by: vida +processed_date: 2026-04-30 priority: medium tags: [noom, GLP-1, behavioral-support, biomarker, digital-health, adherence, microdose] intake_tier: research-task +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content